secwatch.observer — SEC 8-K summary
======================================

Issuer:     AbCellera Biologics Inc. (ABCL)
CIK:        0001703057
Form:       8-K
Filed at:   2022-02-15T23:59:59+00:00
Accession:  0001564590-22-005256
Event type: regulatory
Sentiment:  positive
Materiality: 0.85
Item codes: 7.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

AbCellera-discovered antibody bebtelovimab receives FDA EUA for COVID-19 treatment
--------------------------------------------------------------------------------

- Bebtelovimab (LY-CoV1404) authorized for mild-to-moderate COVID-19 in high-risk patients 12+.
- Neutralizes Omicron including BA.2 and all known variants; binds rarely mutated spike region.
- Second AbCellera antibody from Lilly collaboration; dosage 175 mg IV injection.
- U.S. government agreed to buy up to 600,000 doses by March 2022, option for 500,000 more.
- CEO Hansen highlights potency; previous antibody bamlanivimab also received EUA.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1703057/000156459022005256/0001564590-22-005256-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1703057/000156459022005256/abcl-8k_20220211.htm
  HTML page:      https://secwatch.observer/filing/0001564590-22-005256

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer